Yufei Zhang, Wenbin Yu, Dingding Yuan, Wenqi Ma, Yayi Tu, Bin He
{"title":"Epigenetic therapy for leukemias: a comprehensive review from biological markers to practice","authors":"Yufei Zhang, Wenbin Yu, Dingding Yuan, Wenqi Ma, Yayi Tu, Bin He","doi":"10.1016/j.biotechadv.2025.108626","DOIUrl":null,"url":null,"abstract":"<div><div>Leukemia comprises a group of malignant clonal hematopoietic stem cell disorders where epigenetic abnormalities significantly contribute to its pathogenesis and progression. Epigenetic alterations, such as DNA methylation, histone modifications, and non-coding RNA dysregulation, affect gene expression and cellular function, driving leukemia development. In recent years, therapeutic strategies targeting these epigenetic abnormalities have emerged as a vibrant area of research. DNA methylation is one of the common epigenetic modifications in leukemia. DNA methyltransferase inhibitors (e.g., azidothymidine) are able to reverse aberrant DNA methylation patterns and reactivate silenced oncogenes, thereby inhibiting the proliferation of leukemia cells and inducing apoptosis. Histone acetylase inhibitors and histone methylase inhibitors regulate the acetylation and methylation status of histones, affecting gene expression and cell cycle progression. These drugs inhibit the malignant proliferation and induce differentiation or apoptosis of leukemia cells by altering their epigenetic state. In addition, non-coding RNAs play important roles in the epigenetic regulation of leukemia. By regulating the expression of non-coding RNAs, processes such as proliferation, differentiation and apoptosis of leukemia cells can be affected. In summary, epigenetic therapy for leukemia is a novel therapeutic approach with potential. By intervening against the epigenetic abnormalities of leukemia cells, it can inhibit their malignant proliferation and induce differentiation or apoptosis, thus providing better therapeutic options for leukemia patients. In the future, with the in-depth study of the epigenetic mechanism of leukemia and the development of novel epigenetic drugs, epigenetic therapy is expected to become one of the important means of leukemia treatment.</div></div>","PeriodicalId":8946,"journal":{"name":"Biotechnology advances","volume":"83 ","pages":"Article 108626"},"PeriodicalIF":12.1000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology advances","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0734975025001120","RegionNum":1,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Leukemia comprises a group of malignant clonal hematopoietic stem cell disorders where epigenetic abnormalities significantly contribute to its pathogenesis and progression. Epigenetic alterations, such as DNA methylation, histone modifications, and non-coding RNA dysregulation, affect gene expression and cellular function, driving leukemia development. In recent years, therapeutic strategies targeting these epigenetic abnormalities have emerged as a vibrant area of research. DNA methylation is one of the common epigenetic modifications in leukemia. DNA methyltransferase inhibitors (e.g., azidothymidine) are able to reverse aberrant DNA methylation patterns and reactivate silenced oncogenes, thereby inhibiting the proliferation of leukemia cells and inducing apoptosis. Histone acetylase inhibitors and histone methylase inhibitors regulate the acetylation and methylation status of histones, affecting gene expression and cell cycle progression. These drugs inhibit the malignant proliferation and induce differentiation or apoptosis of leukemia cells by altering their epigenetic state. In addition, non-coding RNAs play important roles in the epigenetic regulation of leukemia. By regulating the expression of non-coding RNAs, processes such as proliferation, differentiation and apoptosis of leukemia cells can be affected. In summary, epigenetic therapy for leukemia is a novel therapeutic approach with potential. By intervening against the epigenetic abnormalities of leukemia cells, it can inhibit their malignant proliferation and induce differentiation or apoptosis, thus providing better therapeutic options for leukemia patients. In the future, with the in-depth study of the epigenetic mechanism of leukemia and the development of novel epigenetic drugs, epigenetic therapy is expected to become one of the important means of leukemia treatment.
期刊介绍:
Biotechnology Advances is a comprehensive review journal that covers all aspects of the multidisciplinary field of biotechnology. The journal focuses on biotechnology principles and their applications in various industries, agriculture, medicine, environmental concerns, and regulatory issues. It publishes authoritative articles that highlight current developments and future trends in the field of biotechnology. The journal invites submissions of manuscripts that are relevant and appropriate. It targets a wide audience, including scientists, engineers, students, instructors, researchers, practitioners, managers, governments, and other stakeholders in the field. Additionally, special issues are published based on selected presentations from recent relevant conferences in collaboration with the organizations hosting those conferences.